+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing how long adults with moderate to severe active rheumatoid arthritis RA continue treatment with Upadacitinib UPA versus tumor necrosis factor inhibitors TNFi under real-world conditions in Germany. This observational study includes about 678 participants across approximately 80 sites and aims to understand treatment persistence over time. Participants will receive either Upadacitinib or a TNFi as prescribed by their doctors according to local labels and standard care practices. The choice of treatment is made independently of the study, and the study does not assign treatments but observes patients receiving these therapies in routine care. During the study, participants will be followed for up to 24 months to monitor how long they continue their prescribed treatment. Researchers will collect data on treatment retention rates and other health information during this period. The total study duration, including recruitment and follow-up, is about 48 months.

Age: 18Years +All Genders
75 locations
O

Actively Recruiting

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Age: 18Years - 100YearsAll Genders
141 locations
O

Actively Recruiting

This research aims to observe the long-term safety of efgartigimod treatment in adults with generalized myasthenia gravis gMG. It compares patients who are starting or have recently started efgartigimod treatment with those who have not been exposed to efgartigimod and are receiving other standard treatments. The study is non-interventional and prospective, focusing on real-world safety outcomes over an extended period. Participants are divided into two groups one receiving efgartigimod and another receiving other medications for myasthenia gravis. This study does not involve any new treatments being administered as part of the trial but monitors patients during their routine care. The study will continue for up to 10 years to gather long-term safety data. During the study, researchers will track the occurrence of serious infections and other safety concerns in both groups. Patients will be monitored through their regular clinical visits without additional interventions from the study. Participants may be followed for up to 10 years to assess safety outcomes associated with their treatments in everyday medical practice.

Age: 18Years +All Genders
35 locations
N

Actively Recruiting

Researchers are evaluating how well asciminib works in patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase Ph CML-CP. The study includes adults who are either newly diagnosed or have previously been treated with one ATP-competitive tyrosine kinase inhibitor TKI. The goal is to understand asciminibs real-world tolerability, safety, and effectiveness compared to other TKIs. Patients are divided into three groups those treated with asciminib who may have had prior TKI treatment, and two groups of newly diagnosed patients treated with either imatinib or second-generation TKIs like dasatinib, bosutinib, or nilotinib. Treatment decisions are made by the patients doctor as part of routine care, and the study observes patients who begin treatment within 14 days before or after enrollment. Participants will be followed through routine visits and asked to complete questionnaires about their health and treatment experience. Researchers will measure molecular responses at various time points up to 24 months, including major molecular response at 12 months. They will also track medication adherence, quality of life, work productivity, and reasons for dose changes or treatment interruptions. The study collects detailed data to assess treatment outcomes and tolerability over time.

Age: 18Years - 100YearsAll Genders
69 locations
P

Actively Recruiting

This research aims to evaluate the safety and tolerability of NSC001, an experimental drug, in people aged 50 to 85 years with mild to moderate Alzheimers disease. NSC001 is designed to target specific brain receptors to potentially improve cognitive and behavioral functions. The study is a randomized, double-blind, placebo-controlled trial conducted across multiple centers to explore both safety and effects on cognition and behavior. Participants will be randomly assigned to one of three groups receiving 40 mg of NSC001 daily, 40 mg of NSC001 daily combined with 20 mg of Trospium, or a placebo with or without 20 mg of Trospium. Treatment and monitoring will occur over 16 weeks, with assessments of drug levels in the blood at specific times. The study includes careful safety monitoring and evaluation of cognitive function throughout the trial. During the study, participants and their caregivers will attend scheduled visits for physical, cognitive, and behavioral assessments. Brain imaging such as MRI or CT scans will be reviewed if available, and tests to confirm Alzheimers diagnosis will be done. Researchers will track medication adherence, collect blood samples, and monitor safety and tolerability. The primary outcomes focus on safety at the start and end of treatment, while secondary measures analyze how the drug behaves in the body over time.

Age: 50Years - 85YearsAll GendersPhase 1Phase 2
10 locations
E

Actively Recruiting

Researchers are evaluating the effects of BAY 3670549 in adults with atrial fibrillation who require electrical cardioversion. The study aims to understand how well BAY 3670549 works to restore normal heart rhythm, how safe and tolerable it is, and how the body processes this medicine. Participants will receive either BAY 3670549 or a placebo to compare outcomes. Each participant will receive a single intravenous infusion of BAY 3670549 or a placebo. After this, researchers will observe whether the heart rhythm returns to normal without needing electrical cardioversion. If the heart rhythm does not revert, electrical cardioversion can still be performed as planned. The study measures how many participants convert to normal rhythm and how quickly, as well as any medical issues after treatment and the medicines pharmacokinetics. Participants will be involved for up to two months. During this time, their heart rhythm will be closely monitored, and safety assessments for any adverse events will be conducted up to 48 hours after treatment. Blood samples will be taken to measure the medicine concentration. The primary outcome is the number of participants whose heart rhythm converts to normal within 3 hours without additional treatment, providing important data on the treatments impact on atrial fibrillation.

Age: 18Years - 85YearsAll GendersPhase 2
30 locations
I

Actively Recruiting

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

Age: 18Years - 75YearsAll Genders
132 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of sovateltide, a new drug candidate, in treating patients with acute cerebral ischemic stroke. This type of stroke occurs when a blood clot blocks blood flow to the brain, causing damage to brain cells. The study builds on earlier clinical trials in India that showed promising results in improving neurological function and recovery with sovateltide, encouraging further testing in the United States and other countries. The trial compares sovateltide combined with standard care against a placebo normal saline plus standard care. Participants will receive three intravenous doses of sovateltide or placebo on days 1, 3, and 6 after stroke onset. Each dose is given as a one-minute IV bolus within 24 hours of stroke symptoms beginning. The study is randomized, double-blind, and placebo-controlled to rigorously assess the treatments impact. Participants will be monitored for 90 days after receiving treatment. Researchers will use several scales to evaluate recovery, including the modified Rankin Scale to measure disability, the National Institutes of Health Stroke Scale for neurological function, and the Barthel Index for daily living activities. Quality of life assessments and cognitive tests will also be done. Safety is closely watched for any adverse events or complications during the study period. The total participation time is about three months following treatment.

Age: 18Years - 80YearsAll GendersPhase 3
54 locations
A

Actively Recruiting

Researchers are collecting data in a registry study for adults diagnosed with acute myeloid leukemia AML, including newly diagnosed and relapsed cases. The study aims to gather important information about the diseases epidemiology, such as patient age and prognostic factors, and to compare incidence and age distribution with population tumor registry data. It also evaluates key clinical outcomes like relapse-free survival, time to relapse, cumulative incidence of relapse, and overall survival. This observational study does not involve treatment assignment but documents treatment strategies used by patients. Data is gathered over a 10-year period to thoroughly monitor outcomes and disease patterns. The registry also collects information on complete remission rates, treatment-related mortality, therapy-associated morbidity, and quality of therapy and diagnosis. Additionally, the study seeks to validate known prognostic factors and explore new ones while describing new therapies and supportive care measures. Participants are adults aged 18 years and older diagnosed with AML according to WHO criteria, including acute promyelocytic leukemia. The study involves long-term follow-up with yearly assessments over 10 years. Researchers will evaluate epidemiological parameters and important survival outcomes. Since this is an observational registry, participants continue with their usual care while data is collected. The study is sponsored by Technische Universitt Dresden and involves multiple sites in Germany.

Age: 18Years +All Genders
60 locations
C

Actively Recruiting

Researchers are evaluating how well nipocalimab works compared to efgartigimod in adults with generalized myasthenia gravis, a condition where the immune system attacks the connection between nerves and muscles causing weakness. This Phase 3b clinical trial aims to compare the effects of these two treatments on muscle strength and daily living activities in participants with confirmed antibody-positive generalized myasthenia gravis who have specific muscle weakness scores. Participants are assigned to one of three groups. One group receives nipocalimab intravenously with a loading dose on Day 1, then maintenance doses every two weeks until Week 12. Another group receives efgartigimod intravenously once a week for four weeks starting from Day 1, with the option to switch to nipocalimab between Week 4 and Week 12. The third group includes participants previously treated with efgartigimod they receive a nipocalimab loading dose on switch day, followed by maintenance doses every two weeks until switch Week 12. During the study, participants are regularly evaluated for changes in immunoglobulin G IgG levels, muscle strength, and daily living activities using standardized scores like the MG-ADL and QMG scales. Safety is closely monitored by tracking adverse events up to Week 20. Follow-up assessments occur at specified weeks to measure treatment effects and participant well-being. The total study duration extends up to 12 weeks of treatment or switch phase with ongoing safety evaluations.

Age: 18Years - 74YearsAll GendersPhase 3
31 locations

1-10 of 18

1